The detection and management of chemotherapy-associated oncological nosologies, cardiovascular toxicity, defined as either an acute cardiac event or a chronic condition, has been tightly integrated into routine oncology care and has become an important component in treatment selection. Some chemotherapeutic agents, such as anthracyclines, are traditionally characterized as cardiotoxic, but cardiovascular side effects are also associated with commonly used molecular targeted drugs. In the last decade, bevacizumab, a monoclonal humanized antibody against vascular endothelial growth factor, has been introduced in the treatment of various metastatic malignancies. Despite its efficacy, bevacizumab has been associated with a significant risk of cardiovascular events such as hypertension, cardiac ischemia, and congestive heart failure. The focus will be on the cardiovascular toxicity of bevacizumab, with the latest data on incidence, clinical spectrum, risk factors, and responsible mechanisms provided.